Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab.

Perez-Soler R, Zou Y, Li T, Ling YH.

Clin Cancer Res. 2011 Nov 1;17(21):6766-77. doi: 10.1158/1078-0432.CCR-11-0545. Epub 2011 Sep 13. Retraction in: Perez-Soler R, Zou Y, Li T, Ling YH. Clin Cancer Res. 2013 Sep 1;19(17):4901.

2.

Skin toxicities associated with epidermal growth factor receptor inhibitors.

Li T, Perez-Soler R.

Target Oncol. 2009 Apr;4(2):107-19. doi: 10.1007/s11523-009-0114-0. Epub 2009 May 19. Review.

PMID:
19452131
3.

Signaling effects of menadione: from tyrosine phosphatase inactivation to connexin phosphorylation.

Abdelmohsen K, Patak P, Von Montfort C, Melchheier I, Sies H, Klotz LO.

Methods Enzymol. 2004;378:258-72. Review. No abstract available.

PMID:
15038974
4.

Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.

Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, Karthaus M, Riess H, Lipp HP, Hauschild A, Trarbach T, Wollenberg A.

Ann Oncol. 2011 Mar;22(3):524-35. doi: 10.1093/annonc/mdq387. Epub 2010 Aug 13.

PMID:
20709812
5.

Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors.

Hofheinz RD, Deplanque G, Komatsu Y, Kobayashi Y, Ocvirk J, Racca P, Guenther S, Zhang J, Lacouture ME, Jatoi A.

Oncologist. 2016 Dec;21(12):1483-1491. Epub 2016 Jul 22. Review.

6.

Mechanisms underlying skin disorders induced by EGFR inhibitors.

Holcmann M, Sibilia M.

Mol Cell Oncol. 2015 Jun 1;2(4):e1004969. doi: 10.1080/23723556.2015.1004969. eCollection 2015 Oct-Dec. Review.

Supplemental Content

Support Center